Home › Funds › BALDWIN WEALTH PARTNERS LLC/MA › NVCT

BALDWIN WEALTH PARTNERS LLC/MA position in NVCT

NUVECTIS PHARMA INC COM · Health Care

BALDWIN WEALTH PARTNERS LLC/MA reported holding 382,015 shares of NVCT (NUVECTIS PHARMA INC COM) in its Q3 2026 13F filing — a position valued at US$8.1M, representing 0.53% of its reported portfolio and ranking #42 among its reported holdings. BALDWIN WEALTH PARTNERS LLC/MA has disclosed NVCT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)382.01K sh
Reported value held$8.07M
Portfolio Weight0.53%
First reportedQ3 2023
Last changeHold
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How BALDWIN WEALTH PARTNERS LLC/MA's NVCT position evolved

BALDWIN WEALTH PARTNERS LLC/MA first disclosed a stake in NVCT in Q3 2023 at 116,380 shares (US$1.5M). The position peaked in Q3 2026 at 382,015 shares, worth US$8.1M. Across 13 filings, BALDWIN WEALTH PARTNERS LLC/MA increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 382,015 shares valued at US$8.1M. Notable position changes include a 104% increase in Q4 2024 (shares rose 81% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 116.38K $1.50M New
Q4 2023 142.04K $1.18M Add
Q1 2024 154.13K $1.26M Add
Q2 2024 168.63K $1.07M Add
Q3 2024 174.13K $1.10M Add
Q4 2024 355.96K $1.93M Add
Q1 2025 358.46K $3.50M Add
Q2 2025 350.46K $2.62M Reduce
Q3 2025 350.46K $2.11M Hold
Q4 2025 389.62K $2.94M Add
Q1 2026 378.62K $2.93M Reduce
Q2 2026 382.01K $7.03M Add
Q3 2026 382.01K $8.07M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NVCT and 13F data

NVCT (NUVECTIS PHARMA INC COM) is a Health Care company. 61 other funds we track also report a position in NVCT — the largest reported positions include TANG CAPITAL MANAGEMENT LLC (US$28.5M), Soleus Capital Management, L.P. (US$18.4M), IRIDIAN ASSET MANAGEMENT LLC/CT (US$14.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NVCT

All NVCT fund holders →

FAQ

How long has BALDWIN WEALTH PARTNERS LLC/MA held NVCT?

BALDWIN WEALTH PARTNERS LLC/MA has disclosed NVCT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BALDWIN WEALTH PARTNERS LLC/MA's current position in NVCT?

As of Q3 2026, BALDWIN WEALTH PARTNERS LLC/MA holds 382.01K shares of NVCT (NUVECTIS PHARMA INC COM), valued at $8.07M, representing 0.53% of its reported portfolio and ranking #42.

Has BALDWIN WEALTH PARTNERS LLC/MA been buying or selling NVCT?

In the latest 13F filing (Q3 2026), BALDWIN WEALTH PARTNERS LLC/MA held unchanged its position in NVCT. The position peaked in Q3 2026 at 382.01K shares.

Which other funds hold NVCT?

Other major institutional holders of NVCT include TANG CAPITAL MANAGEMENT LLC, Soleus Capital Management, L.P., IRIDIAN ASSET MANAGEMENT LLC/CT, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.